Symbol="OCX"
AssetType="Common Stock"
Name="OncoCyte Corp"
Description="OncoCyte Corporation, a molecular diagnostics company, researches, develops, and markets proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company is headquartered in Irvine, California."
CIK="1642380"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES"
Address="1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="29543700"
EBITDA="-21806000"
PERatio="None"
PEGRatio="0"
BookValue="5.29"
DividendPerShare="0"
DividendYield="0"
EPS="-2.54"
RevenuePerShareTTM="0.17"
ProfitMargin="0"
OperatingMarginTTM="-23.05"
ReturnOnAssetsTTM="-0.123"
ReturnOnEquityTTM="-0.238"
RevenueTTM="1101000"
GrossProfitTTM="188000"
DilutedEPSTTM="-2.54"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.954"
AnalystTargetPrice="4.19"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="6.13"
PriceToBookRatio="0.648"
EVToRevenue="2.608"
EVToEBITDA="-0.362"
Beta="1.571"
num_52WeekHigh="19.28"
num_52WeekLow="3.3"
num_50DayMovingAverage="4.026"
num_200DayMovingAverage="6.2"
SharesOutstanding="8240900"
DividendDate="None"
ExDividendDate="None"
symbol="OCX"
open="3.33"
high="3.64"
low="3.33"
price="3.45"
volume="61129.00"
latest_trading_day="2023-08-28"
previous_close="3.32"
change="0.13"
change_percent="3.9157%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="98"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="2"
Volume_recent_avg="240692"
Change_recent_avg="0.01"
Delta_recent_avg="0.08"
Variance_recent_avg="0.04"
Change_ratio_recent_avg="-0.41"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="2"
Aroon_momentum_negative="98"
image_negative_thumbnail_id_1="143"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0033.jpeg"
image_negative_thumbnail_id_2="1145"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0178.jpeg"
image_neutral_thumbnail_id_1="572"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0027.jpeg"
image_neutral_thumbnail_id_2="565"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0034.jpeg"
image_positive_thumbnail_id_1="663"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0045.jpeg"
image_positive_thumbnail_id_2="958"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0120.jpeg"
image_professor_thumbnail_id_1="1190"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0024.jpeg"
image_professor_thumbnail_id_2="1171"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0005.jpeg"
